Additive inhibitory effects of bromocryptine (CB-154) and medroxyprogesterone acetate (MPA) on dimethylbenz[a]anthracene (DMBA)-induced mammary tumors in the rat
- 1 May 1989
- journal article
- research article
- Published by Elsevier in European Journal of Cancer and Clinical Oncology
- Vol. 25 (5) , 891-897
- https://doi.org/10.1016/0277-5379(89)90137-5
Abstract
No abstract availableThis publication has 35 references indexed in Scilit:
- The structure and function of progesterone receptors in breast cancerJournal of Steroid Biochemistry, 1987
- Oral medroxyprogesterone acetate in the treatment of metastatic breast cancerBreast Cancer Research and Treatment, 1985
- Correlation between inhibitory effect on prolactin secretion and antitumor activity of new ergoline compounds on DMBA-induced tumors in ratsEuropean Journal of Cancer and Clinical Oncology, 1983
- Current status of high dose progestin treatment in advanced breast cancerBreast Cancer Research and Treatment, 1983
- Modulation of Pituitary Luteinizing Hormone Releasing Hormone Receptors by Sex Steroids and Luteinizing Hormone Releasing Hormone in the RatBiology of Reproduction, 1982
- Effects of estradiol and prolactin on steroid receptor levels in 7,12-dimethylbenz(a)anthracene-induced mammary tumors and uterus in the ratJournal of Steroid Biochemistry, 1978
- Potent Antidopaminergic Activity of Estradiol at the Pituitary Level on Prolactin ReleaseScience, 1978
- Control of Hormone Receptor Levels and Growth of 7,12-Dimethylbenz(a)anthracene-Induced Mammary Tumors by Estrogens, Progesterone and ProlactinEndocrinology, 1977
- Growth inhibition of rat mammary carcinoma and endocrine changes produced by 2-Br-α-ergocryptine, a suppressor of lactation and nidationPublished by Elsevier ,1970
- Extension of Multiple Range Tests to Group Means with Unequal Numbers of ReplicationsPublished by JSTOR ,1956